Ymmunobio Appoints Dr. Caroline Germa to Board of Directors
Medical oncologist & CMO at Transcenta joins the board of growing biotech company
February 16, 2023 ─ Ymmunobio, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, announced today that Caroline Germa, MD, a medical oncologist with more than two decades’ experience in the pharmaceutical industry, has joined its board of directors.
“With the addition of Dr. Germa’s expertise, we are uniquely positioned to accelerate our asset development from the preclinical stage,” said Ymmunobio Founder and CEO Katrin Rupalla. “We are honored that Dr. Germa has joined our Board and we look forward to working closely to advance our strategy for our novel and first-in-class antibody research.”
“I’m delighted to be joining Ymmunobio’s board,” said Dr. Germa. “The company’s assets represent a strong foundation of novel therapeutic antibodies, and its researchers have a deep understanding of the mechanisms of disease and the importance of cell-to-cell communication to create a response to cancer cells.”
Dr. Germa’s career spans the spectrum of drug development, from early clinical trials to late-phase and registration. Currently the Chief Medical Officer at Transcenta, a clinical-stage biotech company in both oncology and non oncology, Dr. Germa previously served as vice president and head of the Early Development Clinical Group for AstraZeneca’s oncology department. She has also worked for Bristol Myers Squibb as the Vice President and Development Team Lead for a major partnered oncology program and spent seven years at Novartis, where she led the late-phase clinical development of multiple key oncology assets, including the worldwide registration strategy and approval of Ribociclib (CDK4/6 inhibitor – Kisqali®).
Dr. Germa received her medical and medical oncology degrees from Paris and Lille University, France, as well as Breast Disease and Immunology Master Degrees.
Ymmunobio recently signed a transfer ownership agreement with Nagoya University for the license to NPTXR antibodies, which were invented by Professor Mitsuro Kanda, Department of Gastroenterological Surgery, Nagoya University, Japan. The company has begun developing the lead, fully humanized and first in class NPTXR antibody, YB-800, which has demonstrated anti-tumor activity in vivo and in vitro for solid tumors, including several gastro-intestinal and breast cancers.
To learn more about Ymmunobio’s activities and research, visit the website or reach out to info@ymmuno.bio.